Duration 5 min, audio/text in English Breyanzi®- From Mode of Action to administration Breyanzi® is manufactured from the patient’s own CD8- and CD4-positive T cells, which are modified with a viral vector to express a CD19-directed chimeric antigen receptor (CAR). When the CAR-T cell binds to CD19, T cell activation and proliferation are induced, along with secretion of inflammatory cytokines and cytotoxic killing of cancer cells.1 Webinar: 55 minutes Optimizing CAR-T Bridging Therapy in LBCL Listen in to Prof Thorsten Zenz, University Hospital Zürich in Switzerland, providing clinical experiences on timing and bridging therapies before CAR T-cell infusion in aggressive B-cell lymphoma, to gain new insights on how to optimize efficacy and safety of CAR-T in everyday practice. Interview: 2 minutes Post-CAR-T treatment and outpatient setting Listen in to insights on potential management of outpatient care and follow-up of CAR-T treatment in R/R LBCL by Mats Hellström, MD PhD, oncologist, adjunct associate professor at Uppsala University. Interview: 6 minutes How can we improve outcomes for patients with R/R LBCL? Listen to Professor Mats Jerkeman from Skåne University Hospital in Lund, Sweden, as he discusses the treatment gap in R/R LBCL, which patients are suitable for CAR-T, the expected benefits, and the side effect profile associated with CAR-T therapy. Interview: 3 minutes Biomarkers in LBCL Professor Sirpa Leppä, Helsinki University Hospital, share the focus on studying biomarkers to guide physicians in selecting the most appropriate patients for treatment and how to potentially optimize treatment outcomes and minimize the risk of adverse events. Interview: 9 minutes From Clinical Study To Clinical Practice with CAR-T Professor Stephan Mielke, department of hematology and cell therapy at Karolinska university hospital in Stockholm, shares insights from their CAST team, what patients are appropriate for CAR-T, the journey from participating in clinical trials to clinical practice with CAR-T and how the treatment landscape in 2nd and 3rd line is changing in DLBCL. Interview: 2 minutes How to tackle unmet needs in DLBCL? In this interview Professor Sirpa Leppä, Helsinki University Hospital, outlines practical focus areas for the DLBCL working group within the Nordic Lymphoma Group. Listen in to what Prof Leppä shares on high risc populations. Interview: 5 minutes How to become a CAR-T treatment centra MD Renate Galleberg, Haukeland University Hospital Bergen, gives her view on the motivations to improve patient care in aggressive B-cell lymphoma and her lessions from the path to become a CAR-T treatment centra. Interview: 3 minutes How can we improve outcomes for patients with R/R LBCL? Listen to Prof. Sirpa Leppä, Chair of the Nordic Lymphoma Group, as she discusses key focus areas for improving outcomes across different patient groups with aggressive B-cell lymphomas.
